Rapamycin

What it is

Rapamycin inhibits mTOR, a kinase that acts as the cell's central sensor of nutrient availability. When mTOR is active the cell builds; when it is inhibited the cell shifts toward maintenance and autophagy.

It was isolated from soil bacteria on Easter Island, hence the name from Rapa Nui, and approved as an immunosuppressant for kidney transplant.

The animal evidence is the strongest in the field

This is the part that makes rapamycin different from everything else filed under longevity.

The National Institute on Aging's Interventions Testing Program, which tests candidate compounds across multiple independent laboratories specifically to weed out results that will not replicate, found rapamycin extended lifespan in mice. It did so when started at 20 months of age, the rough equivalent of a human in their sixties, and it replicated across sites.

Almost nothing else has cleared that bar. Most compounds marketed for longevity have never been tested that way, and several that were, failed.

What the human evidence actually shows

Considerably less, and the gap is important.

The PEARL trial is the first placebo-controlled randomised trial of intermittent low-dose rapamycin in normally ageing adults. It ran 48 weeks in 114 completers at 5 mg and 10 mg weekly against placebo. Its primary outcome was visceral adiposity, which it did not move.

What it found was a favourable safety profile over a year, with adverse events comparable to placebo and no meaningful disruption of metabolic or immunological biomarkers, plus a signal in women on 10 mg weekly who gained lean tissue mass and reported less pain.

That is a safety result with an exploratory efficacy signal, in 114 people, over one year. It is a genuine and useful contribution, and it is not evidence that rapamycin extends human healthspan. No trial has tested that, and the trial that would take decades.

Practical notes

• Intermittent dosing is the whole premise and it is an inference. The argument is that weekly dosing hits mTORC1 enough to produce the beneficial signalling without the sustained mTORC2 inhibition that causes immunosuppression and insulin resistance. It is biologically reasonable and it has not been demonstrated over the timescales people intend to use it.
• Mouth ulcers are the practical dose-limiter. They are the most common reason people reduce the dose, and they track exposure closely.
• Surgery and infection are the real-world problems. Impaired wound healing is well documented. Anyone taking this needs their surgeon and their doctor to know, which is awkward for a drug obtained through a longevity clinic and not in the main record.
• The mouse data is why serious researchers take it seriously. It is also why the honest position is that a good animal result and a one year human safety trial are not the same thing as knowing this works.

Side effects and warning signs

Commonly reported

• Mouth ulcers, the most characteristic and dose-dependent effect
• Raised cholesterol and triglycerides
• Impaired wound healing
• Acne-like rash
• Reduced insulin sensitivity with continuous dosing

Stop and get medical help

• Any active infection, since the drug suppresses immune function and intermittent dosing has not been shown to eliminate that
• Planned surgery, because impaired wound healing is a documented and clinically significant effect
• Live vaccination while taking it
• New or persistent fever, which needs to be taken more seriously than usual

Sources

1. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results, Aging 2025trial
2. Once-weekly sirolimus on muscle strength and endurance in older adults following a 13-week exercise programmetrial

From the community

Discussion for this compound concentrates in r/longevity and r/Biohackers.

No threads cached yet.

Reddit removed unauthenticated API access, so this section is populated by a build-time script using your own API credentials. Run pnpm fetch:reddit with REDDIT_CLIENT_ID and REDDIT_CLIENT_SECRET set.